Profile picture

Doctor Jonathan Halperin

Mount Sinai Medical Center, New York (United States of America)
Follow
Biography
Jonathan L. Halperin, M.D., F.A.C.C., F.A.H.A., F.A.C.P., M.S.V.M. Jonathan L. Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Associate Director of the Cardiovascular Institute at Mount Sinai Medical Center. He was the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, and directed the trials that evaluated the first oral direct thrombin inhibitor oral factor Xa inhibitor drugs for this indication. He served as Chair of the ACC/AHA Task Force on Practice Guidelines, Co-Chair of the ACC Clinical Competence Committee, as a member of the FDA Cardiovascular and Renal Drugs Advisory Committee, and is Deputy Editor of The Journal of the American College of Cardiology (JACC).
Logo ESC

Contributor content

Enhancing the evidence: latest real-world insights into NOACs for atrial fibrillation
Session
Enhancing the evidence: latest real-world insights into NOACs for atrial fibrillation
28 August 2022
Roundtable discussion: NOACs in patients with atrial fibrillation and comorbidities
Session
Roundtable discussion: NOACs in patients with atrial fibrillation and comorbidities
28 August 2021
Dabigatran use in diverse cardiology settings
Session
Dabigatran use in diverse cardiology settings
25 August 2018
Anticoagulation care: covering all the bases
Session
Anticoagulation care: covering all the bases
26 August 2017
NOACs are not all the same: new factors to consider in 2016
Session
NOACs are not all the same: new factors to consider in 2016
29 August 2016
Cardiac emergencies: how can a reversal agent for a NOAC impact practice?
Session
Cardiac emergencies: how can a reversal agent for a NOAC impact practice?
29 August 2016
Reversal agents for NOACs: what's available and how do they work?
Session
Reversal agents for NOACs: what's available and how do they work?
28 August 2016
World-wide clinical use of NOACs: how are we using them?
Session
World-wide clinical use of NOACs: how are we using them?
30 August 2015
Practical patient protection: celebrating the benefits of dabigatran 5 years on from RE-LY®
Session
Practical patient protection: celebrating the benefits of dabigatran 5 years on from RE-LY®
1 September 2014

ESC 365 is supported by